Oslo Cancer Cluster proudly presents the new members that have joined our organisation during the second quarter of 2019.
The new members represent a valuable addition to our non-profit member organisation, which encompasses the whole oncology value chain. By being a part of Oslo Cancer Cluster, our members are connected to a global network with many relevant key players in the cancer research field. Our members contribute to this unique ecosystem and ensure the development of innovative cancer treatments to improve patients’ lives.
Theradex Oncology provides global clinical development services exclusively to companies developing new cancer treatments. The company has a strong emphasis on early drug development. It provides regulatory and medical support for companies taking cancer treatments into clinical development in the US and Europe.
Theradex Oncology staff has participated in educational events at Oslo Cancer Cluster for a number of years. This is how they became familiar with the cluster.
“Oslo Cancer Cluster provides a unique opportunity to share knowledge with other professionals dedicated to developing new cancer treatments.” Meg Valnoski, President Theradex Oncology
Meg Valnoski explains how the company has been supporting the development of cancer treatments for over 30 years and experienced the advancements in cancer treatments over that time.
“We are always working to expand our knowledge and experience in cancer drug development to support our partnerships with companies developing new therapies for cancer treatment.”
Catapult Life Science is a centre established to bridge the gap between the lab and the industry, providing infrastructure, equipment and expertise for product development and industrialisation in Norway. It has been formed as a result of joint efforts from a range of different players with a common goal of enabling more industrialisation of life science research in Norway, truly what the Norwegians call a dugnad.
“We see Oslo Cancer Cluster as a key partner for realising our purpose, which is to create new opportunities for product development and industrialisation in Norway.” Astrid Hilde Myrset, CEO Catapult Life Science
“Our vision is ‘Bringing science to life’, which implies enabling new ideas to a be developed in Norway for new employment in the pharma industry, new growth in the Norwegian economy, and last but not least, new products to the market, enabling a longer and healthier life for patients.”
This post is part of a series of articles, which will introduce the new members of our organisation every three months.
- To find out who else is involved in Oslo Cancer Cluster, view the full 
- Follow us on  or subscribe to our  to always stay up to date!